☆ 4.5 Article

Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naive non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Health Care Sciences & Services

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study

Rolof G. P. Gijtenbeek et al.

Summary: This study aimed to evaluate the real-world overall survival (OS) of NSCLC patients treated with different generations of EGFR-tyrosine kinase inhibitors (TKI) and identify predictors of survival. The results showed that the survival of Dutch NSCLC patients with EGFR del19 mutation was superior to those with L858R mutation. Osimertinib provided a benefit as first-line treatment in patients with del19 and baseline brain metastases.

LANCET REGIONAL HEALTH-EUROPE (2023)

Add to Collection

Article Oncology

Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L)

Naoki Haratake et al.

Summary: NSCLC patients with L858R mutation may have lower sensitivity to EGFR-TKIs, but the combination therapy of erlotinib plus ramucirumab still shows efficacy. Patients who acquire TKI resistance-associated T790M mutation can benefit from osimertinib. A phase III study will evaluate the clinical efficacy of erlotinib plus ramucirumab compared with osimertinib monotherapy for untreated patients with advanced NSCLC harboring L858R.

CLINICAL LUNG CANCER (2022)

Add to Collection

Article Oncology

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib

Julia Roeper et al.

Summary: TP53 mutations have a negative impact on PFS and OS in patients with EGFR mutations and T790M resistance mutation treated with Osimertinib. Therefore, additional therapeutic and management strategies are needed for this subgroup of patients.

TRANSLATIONAL LUNG CANCER RESEARCH (2022)

Add to Collection

Article Multidisciplinary Sciences

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

Michiel S. van der Heijden et al.

Summary: This study identifies potential predictive biomarkers for survival benefit in patients with platinum-refractory advanced urothelial carcinoma treated with the anti-VEGFR2 monoclonal antibody ramucirumab. Higher PD-L1 IHC and immune pathway scores are associated with greater ramucirumab overall survival (OS) benefit. Basal molecular subtypes show greater OS benefit compared to Luminal subtypes. Patients from East Asia have lower immune/angiogenesis signature scores, correlating with decreased ramucirumab OS benefit. The study highlights the importance of multiple biomarkers in identifying patients who might benefit the most from treatment with ramucirumab.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Oncology

Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review

Francesco Passiglia et al.

Summary: This review summarizes the latest findings on diagnostic testing and therapeutic strategies of EGFR-mutant advanced NSCLC, focusing on the increased detection of rare EGFR mutations and the clinical development of novel selective inhibitors, highlighting the importance of selecting the best EGFR-TKI for specific patient mutations.

TRANSLATIONAL LUNG CANCER RESEARCH (2022)

Add to Collection

Article Respiratory System

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

Rolof G. P. Gijtenbeek et al.

Summary: This study found that in patients with EGFR-mutated NSCLC, intercalated erlotinib with cisplatin-pemetrexed chemotherapy significantly prolonged progression-free survival compared to erlotinib monotherapy, but at the cost of increased toxicity.

ERJ OPEN RESEARCH (2022)

Add to Collection

Article Oncology

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)

Yoshihiko Sakata et al.

Summary: Osimertinib as initial treatment, PD-L1 expression is significantly related to PFS. Adverse events are a noteworthy reason for treatment discontinuation.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Pharmacology & Pharmacy

Sample size calculations for single-arm survival studies using transformations of the Kaplan-Meier estimator

Kengo Nagashima et al.

Summary: This study proposed alternative methods to determine sample sizes based on a valid standard normal approximation, which may provide accurate results even with small sample sizes. Through numerical evaluations via simulations, some of the proposed methods were more accurate, with the method using the arcsine square-root transformation tending to be closer to a prescribed power.

PHARMACEUTICAL STATISTICS (2021)

Add to Collection

Article Oncology

Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors

Jia Liu et al.

Summary: In this multicentre retrospective study, high PD-L1 expression was found to be associated with early resistance to first generation EGFR TKIs and shorter survival in EGFR-mutant lung adenocarcinoma patients, regardless of ethnicity.

LUNG CANCER (2021)

Add to Collection

Article Oncology

Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer

Yufei Yang et al.

Summary: The study revealed that PD-L1 promotes angiogenesis and metastasis of ovarian cancer by interacting with VEGFR2 and activating the FAK/AKT pathway. The oncogenic transcription factor c-JUN was found to regulate PD-L1 expression, leading to poor prognosis in ovarian cancer patients. Combination therapy of PD-L1 inhibitor and anti-angiogenic drugs may be a potential treatment approach for ovarian cancer.

CANCER COMMUNICATIONS (2021)

Add to Collection

Article Oncology

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer

Kazuhiko Nakagawa et al.

Summary: In patients with EGFR-mutated NSCLC, the combination treatment of erlotinib and ramucirumab (RAM+ERL) demonstrated significant clinical benefits for both ex19del and ex21L858R mutation types, with similar treatment outcomes and tolerability. Baseline TP53 co-mutation was associated with improved outcomes in both mutation subtypes.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases

Hiroyasu Kaneda et al.

Summary: This study investigated the safety of ramucirumab administered in combination with erlotinib or osimertinib for EGFR-mutated NSCLC patients with brain metastases. The results showed no dose-limiting toxicity observed, with only one grade 3 hypertension adverse event.

INVESTIGATIONAL NEW DRUGS (2021)

Add to Collection

Article Oncology

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

Akihiro Yoshimura et al.

Summary: Elevated tumor PD-L1 expression is associated with poor outcomes of osimertinib monotherapy in previously untreated advanced NSCLC patients with EGFR mutation. Further clinical trials are warranted to accumulate evidence demonstrating the effectiveness of combination therapy with osimertinib for EGFR-mutated advanced NSCLC patients with elevated tumor PD-L1 expression.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

Add to Collection

Letter Dermatology

Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies

A. Freites-Martinez et al.

ACTAS DERMO-SIFILIOGRAFICAS (2021)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

S. S. Ramalingam et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Kang Qin et al.

BMC CANCER (2020)

Add to Collection

Article Medicine, General & Internal

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

Hao Sun et al.

EBIOMEDICINE (2020)

Add to Collection

Article Oncology

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

Thomas E. Stinchcombe et al.

JAMA ONCOLOGY (2019)

Add to Collection

Article Oncology

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

J. -C. Soria et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Ying Cheng et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Oncology

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Takashi Seto et al.

LANCET ONCOLOGY (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.